Brokers Set Expectations for Crinetics Pharmaceuticals, Inc.’s Q1 2023 Earnings (NASDAQ:CRNX)
→ Buy THIS stock before Taiwan is attacked (From Behind the Markets)
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) – Stock analysts at Lifesci Capital issued their Q1 2023 earnings per share estimates for Crinetics Pharmaceuticals in a research report issued on Monday, March 27th. Lifesci Capital analyst C. Jubinville anticipates that the company will post earnings per share of ($0.69) for the quarter. Lifesci Capital has a “Outperform” rating on the stock. The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.46) per share. Lifesci Capital also issued estimates for Crinetics Pharmaceuticals’ Q2 2023 earnings at ($0.80) EPS, Q3 2023 earnings at ($0.72) EPS, Q4 2023 earnings at ($0.68) EPS and FY2023 earnings at ($2.73) EPS.
Other analysts have also issued reports about the stock. JMP Securities decreased their target price on shares of Crinetics Pharmaceuticals from $50.00 to $41.00 and set a “market outperform” rating on the stock in a research report on Wednesday, March 1st. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Crinetics Pharmaceuticals in a report on Wednesday, March 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Crinetics Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $38.33.
Crinetics Pharmaceuticals Stock Performance
Shares of CRNX stock opened at $15.31 on Wednesday. The firm has a fifty day moving average of $18.91 and a 200-day moving average of $18.31. The stock has a market cap of $825.36 million, a price-to-earnings ratio of -4.84 and a beta of 0.97. Crinetics Pharmaceuticals has a 52-week low of $15.23 and a 52-week high of $27.86.
Hedge Funds Weigh In On Crinetics Pharmaceuticals
Several institutional investors have recently bought and sold shares of CRNX. Great West Life Assurance Co. Can bought a new stake in shares of Crinetics Pharmaceuticals during the third quarter worth $29,000. High Net Worth Advisory Group LLC bought a new stake in Crinetics Pharmaceuticals during the 3rd quarter worth about $39,000. Psagot Value Holdings Ltd. Israel acquired a new stake in Crinetics Pharmaceuticals in the 4th quarter valued at about $46,000. Bourgeon Capital Management LLC bought a new position in shares of Crinetics Pharmaceuticals in the fourth quarter worth about $48,000. Finally, Cubist Systematic Strategies LLC lifted its position in shares of Crinetics Pharmaceuticals by 70.4% during the second quarter. Cubist Systematic Strategies LLC now owns 8,478 shares of the company’s stock worth $158,000 after purchasing an additional 3,503 shares in the last quarter. Institutional investors own 95.64% of the company’s stock.
In related news, insider Stephen F. Betz sold 3,126 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $18.00, for a total transaction of $56,268.00. Following the completion of the sale, the insider now owns 76,151 shares in the company, valued at approximately $1,370,718. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Crinetics Pharmaceuticals news, insider Stephen F. Betz sold 3,126 shares of the business’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $18.00, for a total value of $56,268.00. Following the transaction, the insider now directly owns 76,151 shares in the company, valued at $1,370,718. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Stephen F. Betz sold 8,336 shares of the firm’s stock in a transaction that occurred on Wednesday, January 25th. The stock was sold at an average price of $21.07, for a total transaction of $175,639.52. Following the sale, the insider now directly owns 67,815 shares of the company’s stock, valued at approximately $1,428,862.05. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Crinetics Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Crinetics Pharmaceuticals wasn’t on the list.
While Crinetics Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.